Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.

Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, Garces NI, Janus JR, Liu M, Ma DJ, Moore EJ, Morris JC 3rd, Neben-Wittich M, Price DL, Price KA, Ryder M, Van Abel KM, Hilger C, Samb E, Bible KC.

Thyroid. 2019 Nov;29(11):1615-1622. doi: 10.1089/thy.2019.0086.

PMID:
31595822
2.

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.

Xie H, Yin J, Shah MH, Menefee ME, Bible KC, Reidy-Lagunes D, Kane MA, Quinn DI, Gandara DR, Erlichman C, Adjei AA.

Invest New Drugs. 2019 Aug;37(4):755-762. doi: 10.1007/s10637-019-00797-1. Epub 2019 Jun 6.

PMID:
31172443
3.

Diagnosis and Management of Anaplastic Thyroid Cancer.

Chintakuntlawar AV, Foote RL, Kasperbauer JL, Bible KC.

Endocrinol Metab Clin North Am. 2019 Mar;48(1):269-284. doi: 10.1016/j.ecl.2018.10.010. Review.

PMID:
30717908
4.

European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium.

Luster M, Aktolun C, Amendoeira I, Barczyński M, Bible KC, Duntas LH, Elisei R, Handkiewicz-Junak D, Hoffmann M, Jarząb B, Leenhardt L, Musholt TJ, Newbold K, Nixon IJ, Smit J, Sobrinho-Simões M, Sosa JA, Tuttle RM, Verburg FA, Wartofsky L, Führer D.

Thyroid. 2019 Jan;29(1):7-26. doi: 10.1089/thy.2017.0129. Epub 2019 Jan 7.

PMID:
30484394
5.

Management of treatment-related toxicities in advanced medullary thyroid cancer.

Brose MS, Bible KC, Chow LQM, Gilbert J, Grande C, Worden F, Haddad R.

Cancer Treat Rev. 2018 May;66:64-73. doi: 10.1016/j.ctrv.2018.04.007. Epub 2018 Apr 22. Review.

PMID:
29704768
6.

External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma.

Breen W, Bancos I, Young WF Jr, Bible KC, Laack NN, Foote RL, Hallemeier CL.

Adv Radiat Oncol. 2017 Nov 22;3(1):25-29. doi: 10.1016/j.adro.2017.11.002. eCollection 2018 Jan-Mar.

7.

Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer.

Iñiguez-Ariza NM, Stan MN, Bible KC.

Endocrine. 2018 Jan;59(1):228-229. doi: 10.1007/s12020-017-1464-5. Epub 2017 Nov 1. No abstract available.

PMID:
29094258
8.

Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.

Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, Garces Y, Ma D, Wittich MAN, Rubin J, Richardson R, Morris J, Hay I, Fatourechi V, McIver B, Ryder M, Thompson G, Grant C, Richards M, Sebo TJ, Rivera M, Suman V, Jenkins SM, Smallridge RC, Bible KC.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4506-4514. doi: 10.1210/jc.2017-01180.

PMID:
29029287
9.

OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.

Jasim S, Iniguez-Ariza NM, Hilger CR, Chintakuntlawar AV, Ryder MM, Morris JC 3rd, Bible KC.

Endocr Pract. 2017 Oct;23(10):1254-1261. doi: 10.4158/EP171822.OR. Epub 2017 Aug 17.

PMID:
28816536
10.

Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.

Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC.

Endocrine. 2017 Aug;57(2):220-225. doi: 10.1007/s12020-017-1359-5. Epub 2017 Jul 6.

PMID:
28685225
11.

Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer.

Iñiguez-Ariza NM, Bible KC.

Endocrine. 2017 Sep;57(3):364-365. doi: 10.1007/s12020-017-1342-1. Epub 2017 Jun 22. No abstract available.

PMID:
28643243
12.

"Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy.

Jasim S, Nathan MA, Bible KC.

Endocrine. 2017 Jul;57(1):187-188. doi: 10.1007/s12020-017-1321-6. Epub 2017 May 16. No abstract available.

PMID:
28509079
13.

Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.

Iñiguez-Ariza NM, Ryder MM, Hilger CR, Bible KC.

Thyroid. 2017 Jul;27(7):923-927. doi: 10.1089/thy.2016.0627. Epub 2017 May 31.

PMID:
28471306
14.

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study.

Chintakuntlawar AV, Rumilla KM, Smith CY, Jenkins SM, Foote RL, Kasperbauer JL, Morris JC, Ryder M, Alsidawi S, Hilger C, Bible KC.

J Clin Endocrinol Metab. 2017 Jun 1;102(6):1943-1950. doi: 10.1210/jc.2016-3756.

PMID:
28324060
15.

American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.

Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD.

Thyroid. 2017 Apr;27(4):481-483. doi: 10.1089/thy.2016.0628. Epub 2017 Feb 21. Review.

PMID:
28114862
16.

Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series.

Strajina V, Dy BM, Farley DR, Richards ML, McKenzie TJ, Bible KC, Que FG, Nagorney DM, Young WF, Thompson GB.

Ann Surg Oncol. 2017 Jun;24(6):1546-1550. doi: 10.1245/s10434-016-5739-5. Epub 2017 Jan 5.

PMID:
28058556
17.

Mutated BRAF and personalised medicine in differentiated thyroid cancer.

Bible KC, Ryder M.

Lancet Oncol. 2016 Sep;17(9):1181-3. doi: 10.1016/S1470-2045(16)30230-3. Epub 2016 Jul 23. No abstract available.

PMID:
27460441
18.

Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer.

Bible KC, Chintakuntlawar AV, Ryder M.

J Oncol Pract. 2016 Jun;12(6):521-2. doi: 10.1200/JOP.2016.013144. No abstract available.

PMID:
27288466
19.

New drugs for medullary thyroid cancer: new promises?

Spitzweg C, Morris JC, Bible KC.

Endocr Relat Cancer. 2016 Jun;23(6):R287-97. doi: 10.1530/ERC-16-0104. Epub 2016 May 16. Review.

PMID:
27185870
20.

Evolving molecularly targeted therapies for advanced-stage thyroid cancers.

Bible KC, Ryder M.

Nat Rev Clin Oncol. 2016 Jul;13(7):403-16. doi: 10.1038/nrclinonc.2016.19. Epub 2016 Mar 1. Review.

PMID:
26925962
21.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L.

Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020. Review.

22.

Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group.

Bible KC, Cote GJ, Demeure MJ, Elisei R, Jhiang S, Ringel MD; International Thyroid Oncology Group Correlative Science Committee.

J Clin Endocrinol Metab. 2015 Dec;100(12):4387-95. doi: 10.1210/jc.2015-2818. Epub 2015 Sep 29.

23.

Surgical resection of synchronously metastatic adrenocortical cancer.

Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS, Harmsen WS, Evans DB, Grubbs EG, Bible KC, Young WF, Perrier ND, Que FG, Nagorney DM, Lee JE, Thompson GB.

Ann Surg Oncol. 2015 Jan;22(1):146-51. doi: 10.1245/s10434-014-3944-7. Epub 2014 Aug 5.

PMID:
25092161
24.

Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.

Spitzweg C, Bible KC, Hofbauer LC, Morris JC.

Lancet Diabetes Endocrinol. 2014 Oct;2(10):830-42. doi: 10.1016/S2213-8587(14)70051-8. Epub 2014 Jun 2. Review.

PMID:
24898835
25.

Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.

Isham CR, Netzel BC, Bossou AR, Milosevic D, Cradic KW, Grebe SK, Bible KC.

J Clin Endocrinol Metab. 2014 Jun;99(6):E936-43. doi: 10.1210/jc.2013-2658. Epub 2014 Mar 14.

26.

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C; Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium.

J Clin Endocrinol Metab. 2014 May;99(5):1687-93. doi: 10.1210/jc.2013-3713. Epub 2014 Feb 25.

27.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD.

PLoS Genet. 2014 Feb 13;10(2):e1004135. doi: 10.1371/journal.pgen.1004135. eCollection 2014 Feb.

28.

Operative intervention for recurrent adrenocortical cancer.

Dy BM, Wise KB, Richards ML, Young WF Jr, Grant CS, Bible KC, Rosedahl J, Harmsen WS, Farley DR, Thompson GB.

Surgery. 2013 Dec;154(6):1292-9; discussion 1299. doi: 10.1016/j.surg.2013.06.033.

PMID:
24238048
29.

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.

Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA.

Invest New Drugs. 2013 Oct;31(5):1201-6. doi: 10.1007/s10637-013-0004-2. Epub 2013 Jul 26.

30.

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R.

J Clin Endocrinol Metab. 2013 Jun;98(6):2392-400. doi: 10.1210/jc.2013-1106. Epub 2013 Apr 15.

31.

Taking stock of therapeutic progress in metastatic radioactive iodine-refractory differentiated thyroid cancer: what's next?

Bible KC.

Thyroid. 2013 Apr;23(4):383-4. doi: 10.1089/thy.2013.0073. No abstract available.

PMID:
23398107
32.

Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.

Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA, Bible KC.

Sci Transl Med. 2013 Jan 2;5(166):166ra3. doi: 10.1126/scitranslmed.3004358.

33.

American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.

Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM; American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce.

Thyroid. 2012 Nov;22(11):1104-39. doi: 10.1089/thy.2012.0302.

PMID:
23130564
34.

Individualization of therapies for patients with advanced differentiated thyroid cancers.

Bible KC.

J Clin Endocrinol Metab. 2012 Sep;97(9):3092-3. doi: 10.1210/jc.2012-2676. No abstract available.

PMID:
22962671
35.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

J Oncol Pract. 2012 May;8(3 Suppl):e1s-5s. doi: 10.1200/JOP.2011.000496.

36.

Treating advanced radioresistant differentiated thyroid cancer.

Bible KC.

Lancet Oncol. 2012 Sep;13(9):854-5. doi: 10.1016/S1470-2045(12)70342-X. Epub 2012 Aug 14. No abstract available.

PMID:
22898677
37.

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.

Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, Karlin NJ, Traynor AM, Kumar P, Goh BC, Lim WT, Bossou AR, Isham CR, Webster KP, Kukla AK, Bieber C, Burton JK, Harris P, Erlichman C; Mayo Phase 2 Consortium; Mayo Clinic Endocrine Malignances Disease Oriented Group.

J Clin Endocrinol Metab. 2012 Sep;97(9):3179-84. Epub 2012 Jul 6.

38.

Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models.

Reddi HV, Madde P, Cohen YC, Bangio L, Breitbart E, Harats D, Bible KC, Eberhardt NL.

Genes Cancer. 2011 Oct;2(10):993-5. doi: 10.1177/1947601912437933.

39.

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV, Casler JD, Karlin NJ, Westphal SA, Richardson RL, Buckner JC, Erlichman C.

Am J Manag Care. 2012 May 1;18(5):e162-7.

PMID:
22694109
40.

A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

Bible KC, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL, Boente M, Burton JK, Gomez Dahl LC, Tibodeau JD, Isham CR, Maguire JL, Shridhar V, Kukla AK, Voll KJ, Mauer MJ, Colevas AD, Wright J, Doyle LA, Erlichman C; Mayo Phase 2 Consortium (P2C); North Central Cancer Treatment Group (NCCTG).

Gynecol Oncol. 2012 Oct;127(1):55-62. Epub 2012 Jun 1.

41.

Toward improved outcomes in patients with anaplastic thyroid cancer.

Bible KC, Foote RL, Smallridge RC.

Oncology (Williston Park). 2012 Apr;26(4):398, 401, 406. No abstract available.

42.

Systemic therapeutic approaches to advanced thyroid cancers.

Menefee ME, Smallridge RC, Bible KC.

Am Soc Clin Oncol Educ Book. 2012:389-92. doi: 10.14694/EdBook_AM.2012.32.389.

PMID:
24451769
43.

The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation.

Isham CR, Tibodeau JD, Bossou AR, Merchan JR, Bible KC.

Br J Cancer. 2012 Jan 17;106(2):314-23. doi: 10.1038/bjc.2011.522. Epub 2011 Dec 20.

44.

Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.

Harris PJ, Bible KC.

Expert Opin Investig Drugs. 2011 Oct;20(10):1357-75. doi: 10.1517/13543784.2011.614230. Review.

45.

Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy.

Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC.

Thyroid. 2011 Jan;21(1):25-30. doi: 10.1089/thy.2010.0220. Epub 2010 Dec 16.

PMID:
21162687
46.

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium.

Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5. Epub 2010 Sep 17.

47.

Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.

Sideras K, Menefee ME, Burton JK, Erlichman C, Bible KC, Ivy SP.

J Clin Oncol. 2010 Jul 1;28(19):e312-3. doi: 10.1200/JCO.2009.26.4432. Epub 2010 Jun 1. No abstract available.

PMID:
20516434
48.
49.

The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase.

Tibodeau JD, Benson LM, Isham CR, Owen WG, Bible KC.

Antioxid Redox Signal. 2009 May;11(5):1097-106. doi: 10.1089/ARS.2008.2318.

50.

Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.

Le SB, Hailer MK, Buhrow S, Wang Q, Flatten K, Pediaditakis P, Bible KC, Lewis LD, Sausville EA, Pang YP, Ames MM, Lemasters JJ, Holmuhamedov EL, Kaufmann SH.

J Biol Chem. 2007 Mar 23;282(12):8860-72. Epub 2007 Jan 9.

Supplemental Content

Loading ...
Support Center